RTA 408 Capsules in Patients With Friedreich's Ataxia - MOXIe

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02255435

Recruitment Status : Active, not recruiting

First Posted : October 2, 2014

Last Update Posted : March 24, 2022

Sponsor:

Collaborators:

AbbVie

Friedreich's Ataxia Research Alliance

Information provided by (Responsible Party):

Reata Pharmaceuticals, Inc.

Study Description

Brief Summary:

Friedreich's ataxia is an autosomal recessive cerebellar ataxia caused by triplet-repeat expansions. The causative mutation is a trinucleotide (GAA) repeat expansion in the first intron of the frataxin gene, leading to impaired transcription of frataxin. The pathological consequences of frataxin deficiency include a severe disruption of iron-sulfur cluster biosynthesis, mitochondrial iron overload coupled to cellular iron dysregulation, and an increased sensitivity to oxidative stress.

A hallmark of Friedreich's ataxia is impairment of antioxidative defense mechanisms, which play a major role in disease progression. Studies have demonstrated that nuclear factor erythroid-derived 2-related factor 2 (Nrf2) signaling is grossly impaired in patients with Friedreich's ataxia. Therefore, the ability of omaveloxolone (RTA 408) to activate Nrf2 and induce antioxidant target genes is hypothesized to be therapeutic in patients with Friedreich's ataxia.

This 2-part study will evaluate the efficacy, safety, and pharmacodynamics of omaveloxolone (RTA 408) in the treatment of patients with Friedreich's ataxia.

Part 1: The first part of this study will be a randomized, placebo-controlled, double-blind, dose-escalation study to evaluate the safety of omaveloxolone (RTA 408) at various doses in patients with Friedreich's ataxia.

Part 2: The second part of this study is a randomized, placebo-controlled, double-blind, parallel-group study to evaluate the safety and efficacy of omaveloxolone (RTA 408) 150 mg in patients with Friedreich's ataxia. Patients enrolled in Part 2 will be randomized 1:1 to receive omaveloxolone (RTA 408) 150 mg or placebo.

Extension: The extension will assess long-term safety and tolerability of omaveloxolone (RTA 408) in qualified patients with Friedreich's ataxia following completion of Part 1 or Part 2. Patients will not be unblinded to study treatment in Part 1 or Part 2 upon entering the extension study. Patients will receive open-label omaveloxolone (RTA 408) at 150 mg once daily.

Condition or disease	Intervention/treatment	Phase
Friedreich Ataxia	Drug: Omaveloxolone Capsules, 2.5 mg Drug: Omaveloxolone Capsules, 5 mg Drug: Omaveloxolone Capsules, 10 mg Drug: Placebo Drug: Omaveloxolone Capsules, 20 mg Drug: Omaveloxolone Capsules, 40 mg Drug: Omaveloxolone Capsules, 80 mg Drug: Omaveloxolone Capsules, 160 mg Drug: Omaveloxolone Capsules, 300 mg Drug: Omaveloxolone Capsules, 150 mg	Phase 2

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	172 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	Double (Participant, Investigator)
Primary Purpose:	Treatment
Official Title:	A Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Friedreich's Ataxia (MOXIe)
Study Start Date :	January 2015
Actual Primary Completion Date :	October 3, 2019
Estimated Study Completion Date :	December 2022

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: VLDLR-associated cerebellar hypoplasia Friedreich ataxia Autosomal recessive cerebellar ataxia type 1

MedlinePlus related topics: Friedreich Ataxia

Genetic and Rare Diseases Information Center resources: Friedreich Ataxia Spinocerebellar Ataxia

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: Omaveloxolone Capsules 2.5 and 5 mg omaveloxolone (RTA 408) Capsules, 2.5 mg taken orally one daily for 2 weeks, then 5 mg taken orally once daily for 10 weeks	Drug: Omaveloxolone Capsules, 2.5 mg Other Name: RTA 408 Capsules 2.5 mg Drug: Omaveloxolone Capsules, 5 mg Other Name: RTA 408 capsules, 5 mg
Experimental: Omaveloxolone Capsules 10 mg omaveloxolone (RTA 408) Capsules, 10 mg taken orally once daily for 12 weeks	Drug: Omaveloxolone Capsules, 10 mg Other Name: RTA 408 capsules, 10 mg
Placebo Comparator: Placebo Capsules Placebo capsules taken orally once daily for 12 weeks	Drug: Placebo
Experimental: Omaveloxolone Capsules 20 mg omaveloxolone (RTA 408) Capsules, 20 mg taken orally once daily for 12 weeks	Drug: Omaveloxolone Capsules, 20 mg Other Name: RTA 408 capsules, 20 mg
Experimental: Omaveloxolone Capsules 40 mg omaveloxolone (RTA 408) Capsules, 40 mg taken orally once daily for 12 weeks	Drug: Omaveloxolone Capsules, 40 mg Other Name: RTA 408 capsules, 40 mg
Experimental: Omaveloxolone Capsules 80 mg omaveloxolone (RTA 408) Capsules, 80 mg taken orally once daily for 12 weeks	Drug: Omaveloxolone Capsules, 80 mg Other Name: RTA 408 capsules, 48 mg
Experimental: Omaveloxolone Capsules 160 mg omaveloxolone (RTA 408) Capsules, 160 mg taken orally once daily for 12 weeks	Drug: Omaveloxolone Capsules, 160 mg Other Name: RTA 408 capsules, 160 mg
Experimental: Omaveloxolone Capsules 300 mg omaveloxolone (RTA 408) Capsules, 300 mg taken orally once daily for 12 weeks	Drug: Omaveloxolone Capsules, 300 mg Other Name: RTA 408 capsules, 300 mg
Experimental: Omaveloxolone Capsules 150 mg omaveloxolone (RTA 408) Capsules, 150 mg taken orally once daily for 24 weeks	Drug: Omaveloxolone Capsules, 150 mg Other Name: RTA 408 capsules, 150 mg

Outcome Measures

Primary Outcome Measures :

Measure the change in the modified Friedreich's ataxia rating scale (FARS) [ Time Frame: 48 weeks ]

Secondary Outcome Measures :

Measure the change of peak workload (in watts/kg) during exercise testing [ Time Frame: 48 weeks ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	16 Years to 40 Years (Child, Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Have genetically confirmed Friedreich's ataxia
Have a modified FARS score ≥20 and ≤80
Be male or female and ≥16 years of age and ≤40 years of age
Have no changes to exercise regimen within 30 days prior to Study Day 1 and be willing to remain on the same exercise regimen during the 16-week study period
Have the ability to complete maximal exercise testing
Be able to swallow capsules

Exclusion Criteria:

Have uncontrolled diabetes (HbA1c >11.0%)
Have B-type natriuretic peptide value >200 pg/mL
Have a history of clinically significant left-sided heart disease and/or clinically significant cardiac disease
Have known active fungal, bacterial, and/or viral infection, including human immunodeficiency virus or hepatitis virus (B or C)
Have known or suspected active drug or alcohol abuse
Have clinically significant abnormalities of clinical hematology or biochemistry, including but not limited to elevations greater than 1.5 times the upper limit of normal of aspartate aminotransferase, or alanine aminotransferase
Have any abnormal laboratory test value or serious pre-existing medical condition that, in the opinion of the investigator, would put the patient at risk by study enrollment
Have taken any of the following drugs within 7 days prior to Study Day 1 or plan to take any of these drugs during the time of study participation:
1. Sensitive substrates for cytochrome P450 2C8 or 3A4 (e.g., repaglinide, midazolam, sildenafil)
2. Moderate or strong inhibitors or inducers of cytochrome P450 3A4 (e.g., carbamazepine, phenytoin, ciprofloxacin, grapefruit juice)
3. Substrates for p-glycoprotein transporter (e.g., ambrisentan, digoxin)
Have participated in any other interventional clinical study within 30 days prior to Study Day 1
Have a cognitive impairment that may preclude ability to comply with study procedures
Prior participation in a trial with omaveloxolone (RTA 408)

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02255435

Locations

Layout table for location information

United States, California
UCLA
Los Angeles, California, United States, 90095
United States, Florida
University of Florida - Neurology
Gainesville, Florida, United States, 32610
USF Ataxia Research Center
Tampa, Florida, United States, 33612
United States, Georgia
Emory University Hospital - Neurology
Atlanta, Georgia, United States, 30329
United States, Iowa
University of Iowa Stead Family Children's Hospital
Iowa City, Iowa, United States, 52242
United States, Ohio
Ohio State University - Neurology
Columbus, Ohio, United States, 43221
United States, Pennsylvania
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104
Australia, Victoria
Murdoch Childrens Research Institute
Parkville, Victoria, Australia, 3052
Austria
Medical University Innsbruck
Innsbruck, Austria, 6020
Italy
Neurological Institute Carlo Besta
Milan, Italy, 20133
United Kingdom
University College of London
London, United Kingdom, WC1E 6BT

Sponsors and Collaborators

Reata Pharmaceuticals, Inc.

AbbVie

Friedreich's Ataxia Research Alliance

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Lynch DR, Chin MP, Delatycki MB, Subramony SH, Corti M, Hoyle JC, Boesch S, Nachbauer W, Mariotti C, Mathews KD, Giunti P, Wilmot G, Zesiewicz T, Perlman S, Goldsberry A, O'Grady M, Meyer CJ. Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study). Ann Neurol. 2021 Feb;89(2):212-225. doi: 10.1002/ana.25934. Epub 2020 Nov 5.

Lynch DR, Farmer J, Hauser L, Blair IA, Wang QQ, Mesaros C, Snyder N, Boesch S, Chin M, Delatycki MB, Giunti P, Goldsberry A, Hoyle C, McBride MG, Nachbauer W, O'Grady M, Perlman S, Subramony SH, Wilmot GR, Zesiewicz T, Meyer C. Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia. Ann Clin Transl Neurol. 2018 Nov 10;6(1):15-26. doi: 10.1002/acn3.660. eCollection 2019 Jan.

Layout table for additonal information

Responsible Party:	Reata Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:	NCT02255435
Other Study ID Numbers:	RTA 408-C-1402
First Posted:	October 2, 2014 Key Record Dates
Last Update Posted:	March 24, 2022
Last Verified:	March 2022

Keywords provided by Reata Pharmaceuticals, Inc.:


RTA 408 RTA 408 Capsules Oxidative Stress Mitochondrial dysfunction omaveloxolone

Additional relevant MeSH terms:

Layout table for MeSH terms

Ataxia Cerebellar Ataxia Friedreich Ataxia Dyskinesias Neurologic Manifestations Nervous System Diseases Cerebellar Diseases Brain Diseases	Central Nervous System Diseases Spinocerebellar Degenerations Spinal Cord Diseases Heredodegenerative Disorders, Nervous System Neurodegenerative Diseases Genetic Diseases, Inborn Mitochondrial Diseases Metabolic Diseases

To Top